Fetal Hemoglobin Inducing Compounds for Anemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for β-thalassemia and sickle cell disease, such as hydroxyurea, have variable efficacy, low specificity in globin gene induction, and high toxicity, with approximately 25% of patients being non-responders and experiencing side effects like myelosuppression and reproductive toxicity.
Innovation Solution
Development of novel compounds that induce the expression of endogenous embryonic/fetal globin chains in erythrocytes, represented by specific chemical formulas, which are administered to patients to treat anemia associated with β-thalassemia or sickle cell disease by inducing globin gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If hydroxyurea is used to induce fetal hemoglobin production, then HbF levels increase, but toxicity increases and specificity decreases
Solution Approach 1:
The patent changes the chemical parameters by using alternative compounds (such as I-BET151, a bromodomain inhibitor) instead of hydroxyurea to induce HbF production. This parameter change in the inducing agent achieves the desired effect of increasing fetal hemoglobin while reducing the toxic side effects associated with hydroxyurea treatment.
2Quantity of substance
If hydroxyurea is used to treat hemoglobinopathies, then HbF production is stimulated, but myelosuppression and reproductive toxicity occur
Solution Approach 1:
The patent extracts the desired therapeutic effect (HbF induction) from the harmful context (hydroxyurea toxicity) by identifying and using alternative compounds that can stimulate fetal hemoglobin production through different mechanisms, thereby separating the beneficial effect from the harmful side effects.
3Reliability
If conventional treatments are used for β-thalassemia and sickle cell disease, then clinical symptoms are addressed, but variable efficacy and low specificity in globin gene induction occur
Solution Approach 1:
The patent applies local quality by using compounds that specifically target and modify particular globin gene expression patterns. The alternative inducing agents demonstrate enhanced specificity for fetal globin gene induction while maintaining clinical efficacy, thereby improving the precision of the therapeutic action.
Data Source
AI summary
Compounds, pharmaceutical compositions, and methods for treating anemia (β-thalassemia anemia or sickle cell anemia.